Desvenlafaxine Tablet, Extended Release
Product Images NDC 46708-152

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 46708-152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine-100mg.jpg (Desvenlafaxine 100mg)

This is a description of a medicine labeled as "SEALED FOR YOUR PROTECTION". The tablets contain 100 mg of desvenlafaxine and are intended for extended release. The recommended dosage and manufacturer details are given alongside storage instructions of keeping the tablets between 20°C to 25°C. These tablets should be dispensed with a medication guide for each patient. The batch number is B0, and the medicine is intended to be dispensed by a licensed pharmacist.*

FDA Label Image

Figure 1 (Desvenlafaxine 1figure)

The text describes a figure (Figure 1) showing the impact of other drugs on the pharmacokinetics (PK) of Desvenlafaxine. The figure includes recommendations for adjusting dosage based on the fold change and 90% CI values for different inhibitors of the CYP3A4 enzyme. For example, the Cmax value for Desvenlafaxine is reduced by 4 when administered with Ketoconazole, but no dose adjustment is recommended. The text does not provide enough information to understand the full context or purpose of the figure.*

FDA Label Image

Figure 2 (Desvenlafaxine 2figure)

This is a table (Figure 2) that shows the impact of Desvenlafaxine on the pharmacokinetics of three drugs, namely Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The table shows the change in pharmacokinetics due to the interaction of Desvenlafaxine with these drugs. It also provides recommendations on dose adjustment for each drug based on the changes observed in pharmacokinetics.*

FDA Label Image

Figure 3 (Desvenlafaxine 3figure)

This is a table presenting the impact of intrinsic factors such as renal impairment, hepatic impairment, and population description on PK parameters (Cmax, AUC) regarding an unspecified drug. Each intrinsic factor has different categories such as mild, moderate, severe, and end-stage renal disease (ESRD). The population description includes age and gender categories. The table shows the fold change and 90% CI recommendation for dosing adjustments or no adjustment. However, there is not enough information to provide specific recommendations since the drug and the PK parameters are undefined.*

FDA Label Image

Desvenlafaxine-50mg.jpg (Desvenlafaxine 50mg)

This is a pharmaceutical label for Desvenlafaxine extended-release tablets containing 50 mg of medication per tablet. It includes information on dosage and storage, as well as the manufacturing company Alembic Pharmaceuticals Limited located in Gujarat, India. The NDC code, lot number, and license for the medication are also provided. A medication guide should be provided to each patient along with the 30-tablet prescription.*

FDA Label Image

Structure (Desvenlafaxine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.